Moors & Cabot, Inc.
- SEC CIK
- 0001607239
- Latest filing
- Aug 10, 2026
CRSP holding history
CRISPR Therapeutics AG in every 13F filed by Moors & Cabot, Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CRSP overviewAll 13F holders of CRSPFull Q2 2026 holdings
- Shares (Q2 2026)
- 6,732
- Value
- $367.2K
- % of portfolio
- <0.1%
- Quarters held
- 10
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 6,732 | $367.2K | <0.1% | +1,775+35.8% | Added | Holders |
| Q1 2026 | 4,957 | $235.8K | <0.1% | −90−1.8% | Reduced | Holders |
| Q4 2025 | 5,047 | $264.7K | <0.1% | −108−2.1% | Reduced | Holders |
| Q3 2025 | 5,155 | $334.1K | <0.1% | −300−5.5% | Reduced | Holders |
| Q2 2025 | 5,455 | $265.3K | <0.1% | +5,455 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −2,963−100.0% | Sold out | Holders |
| Q1 2024 | 2,963 | $202.0K | <0.1% | −620−17.3% | Reduced | Holders |
| Q4 2023 | 3,583 | $224.3K | <0.1% | +3,583 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −2,035−100.0% | Sold out | Holders |
| Q3 2021 | 2,035 | $228.0K | <0.1% | +150+8.0% | Added | Holders |
| Q2 2021 | 1,885 | $305.0K | <0.1% | +145+8.3% | Added | Holders |
| Q1 2021 | 1,740 | $212.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.